A recent analysis compared the care of patients with RA with that received by patients with gout, finding that hospitalization and costs for patients with gout have increased, but both are decreasing for patients with RA. Unlike RA, significant advances in treatment have not been made for gout, despite its increasing prevalence, and patients may land in the hospital unnecessarily…
Search results for: gout flare
Treatment Options for Severe Refractory Gout When Pegloticase Fails
Pegloticase is a new alternative therapy for patients with severe, refractory gout unresponsive to other urate-lowering agents. The goal of this therapy is to reduce disease burden, tophi size and frequency of flares and to improve quality of life when other treatments have failed. Persistent lowering of plasma uric acid (PUA) to less than 6…
Patient-Centered Care Model for RA Flares Could Improve Self-Management of Symptoms
A recent trend to incorporate patient-reported outcomes (PROs) in clinical research, and ultimately clinical practice, is a response to the need to better measure and treat what patients truly care about, and adapt to the changing healthcare environment, which increasingly includes patient satisfaction as a key metric for overall quality of care, a metric tied…
New Gout Criteria from the ACR/EULAR Focus on Clinical Trials, Global Standards
Gout affects nearly 4% of American adults, causing joint inflammation, pain and crystal deposits that may lead to bone erosion over time. At least five different classification criteria for gout are used worldwide, creating potential discrepancies in clinical trial enrollment and eventual results. An international panel of investigators collaborated to create new, standardized gout classification…
Genetic Screening May Prevent Adverse Gout Treatment Reaction
Screening gout patients for the HLA-B*58:01 allele may help rheumatologists determine more effective treatments and a patient’s risk of allopurinol-induced severe cutaneous adverse reactions…
FDA Reviewers Question Safety of AstraZeneca’s Gout Drug
(Reuters)—The U.S. Food and Drug Administration staff reviewers have raised concerns about kidney- and heart-related side effects noted in trials on AstraZeneca Plc’s gout treatment, especially at higher doses. FDA reviewers, in a preliminary review published on Wednesday, expressed concerns over higher death rates related to the side effects in patients who took the drug,…
Rheumatology Coding Corner Question: Office Visit for Chronic Idiopathic Gout
Follow-up Visit with Time A 62-year-old male patient returns to the office for a follow-up visit for chronic idiopathic gout without tophi. The patient’s present uric acid level is 4.0, and he is now taking allopurinol 450 mg per day. Previously, he was taken off indapamide due to an increase in his uric acid. He…
Phase 3 Studies Evaluate Lesinurad for Gout Treatment
For 12 months, two studies examined the use of lesinurad in combination with allopurinol to treat gout, with patients achieving reduced serum uric acid levels and demonstrating no severe toxicity.
Generic Colchicine Approved for Gout Prophylaxis
The cost for therapeautic gout treatment may soon go down, thanks to a recent court ruling
2014 ACR/ARHP Annual Meeting: New Directions for Gout
Economics of care, more aggressive treatment targets needed for better gout management
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 15
- Next Page »